Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
Duke-NUS Medical School invites applications for a Post-doctoral Research Fellow to lead the NK cell research program. The role focuses on design, expansion, and functional testing of NK cell products against hematologic and solid tumours in pre-clinical models.
The successful candidate will optimize NK cell expansion platforms, perform functional assays, and conduct in vivo studies to assess persistence and anti-tumour activity, with opportunities for publications and grant support.
University-Level Unit: Duke-NUS Medical School
Faculty/Department-Level Unit: Office of Research
Employee Category: Research Staff
Posting Start Date: 21/09/2026
We are a fast-moving translational research lab driven by the need to develop curative, immune-based therapies for blood cancers such as chronic myeloid leukaemia (CML) and for Asian-specific solid tumours including nasopharyngeal cancer. A central pillar of our programme is harnessing natural killer (NK) cells as off-the-shelf cellular therapeutics that can eliminate malignant cells across both haematological and solid tumour settings. We combine leading-edge multi-omics single-cell profiling with AI/ML-guided discovery to define the mechanisms that govern NK cell fitness, persistence, and tumour recognition, then rigorously validate these findings using state-of-the-art platforms including NK cell in vitro expansion systems, engineered feeder and iPSC-based technologies, advanced functional assays, and in vivo tumour models. Our current work spans engineering and expanding NK cells for enhanced cytotoxicity and in vivo persistence, dissecting NK cell-tumour interactions within the immunosuppressive microenvironment of solid tumours, and deploying NK cell-based strategies to eliminate persistent leukaemia stem cells (LSCs) in minimal residual disease and prevent disease transformation. We seek a talented and driven post-doctoral Research Fellow to lead the design, expansion, and functional testing of NK cell products and to evaluate their anti-tumour activity in relevant pre-clinical models.
We regret that only shortlisted candidates will be notified.